Clinical trial · Observational
Evaluating Disparities in Precision Oncology
Evaluating Disparities in Precision Oncology: An Observational Trial in the Context of a Real-World Academic Practice Model
NCT06081517CI-TRIAL-00114904EDPOrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a non-randomized observational trial designed to collect detailed clinical, social determinant, and genomic data from patients enrolled in molecular oncology tumor boards across four comprehensive cancer centers.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
| Metastatic Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Social Determinants of Health and toxicity questionnaires | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Black patients with advanced cancer
- interventionNames
- Behavioral: Social Determinants of Health and toxicity questionnaires
- label
- Non Black patients with advanced cancer
- interventionNames
- Behavioral: Social Determinants of Health and toxicity questionnaires
Primary outcomes (2)
- measure
- Compare Overall Survival between Black patients and White patients (self-reported race) with advanced cancer
- timeFrame
- through study completion (i.e. death, lost to follow up, or withdraw)-up to 5 years
- measure
- Compare rate of new onset or worsening therapy- induced peripheral neuropathy (TIPN) between Black patients and White patients with advanced cancer prospectively exposed to a taxane
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Ability to provide written informed consent and HIPAA authorization 2. Patients must be ≥ 18 years old at the time of consent 3. Patients who have or are planning to undergo molecular testing as part of their routine cancer care Exclusion Criteria: N/A
References
Publications (0)
Data not yet available
No reference posted for this study.